McKesson Corporation has announced its agreement to acquire a controlling 80% interest in PRISM Vision Holdings, LLC, investing approximately $850 million to expand its leadership in retina and ophthalmology care. PRISM Vision, a leading provider of general ophthalmology and retina management services, will see its physicians retain the remaining 20% interest.
“The acquisition of PRISM Vision will allow McKesson to build on our leadership in community practice and specialty solutions, while building a platform to serve the high-growth area of retina and ophthalmology,” said Brian Tyler, chief executive officer of McKesson. “PRISM Vision has a strong track record and value proposition for community-based physicians and a strong leadership team focused on delivering superior retinal care, enhancing the provider experience and delivering innovative clinical research capabilities. We intend to develop a leading platform for retinal care, delivering differentiated solutions and value across providers, biopharma partners and patients. McKesson has a long track record of leading practice management and clinical research outcomes with our differentiated Oncology platform, and we are excited to leverage this expertise to serve the high-growth area of retina and ophthalmology. This will allow us to expand our suite of solutions and continue to pursue our purpose of advancing health outcomes for all.”
This acquisition aligns with McKesson’s strategy to enhance its specialty care platform by leveraging PRISM’s extensive network of over 180 providers, 91 office locations, and seven ambulatory surgery centers. The company seeks to drive clinical quality, expand data-based analytics, and foster biopharma partnerships while improving patient care and outcomes.
Expanding McKesson’s Specialty Care Capabilities
The acquisition of PRISM Vision marks a strategic move for McKesson to develop a leading presence in the high-growth retina and ophthalmology sectors. Key objectives for McKesson include:
- Developing a cutting-edge retinal and ophthalmology care platform, offering enhanced clinical services and distribution solutions.
- Expanding data analytics capabilities to drive better clinical insights and patient outcomes.
- Investing in innovative clinical research to improve patient access to effective treatments.
- Deepening biopharma partnerships to provide new solutions and therapies.
“McKesson’s long history of supporting specialty physicians by emphasizing clinical quality and enhancing patients’ access to care, is completely aligned with the core values and culture of PRISM Vision Group,” said Dr. Steven Madreperla, chief executive officer of PRISM Vision. “We are thrilled to be able to bring together PRISM’s exceptional provider base and service delivery platform with McKesson’s deep expertise in care delivery to further develop and expand our eye care network together.
Financial and Business Impacts
Once the acquisition is finalized, PRISM Vision will be consolidated within McKesson’s U.S. Pharmaceutical segment. The transaction is anticipated to be accretive to McKesson’s Adjusted Earnings Per Diluted Share, contributing $0.20 to $0.30 in the first 12 months following closure and $0.65 to $0.75 within three years.
Completion of the transaction is subject to regulatory approvals and customary closing conditions.
By acquiring PRISM Vision, McKesson continues its mission of advancing health outcomes for all, further cementing its standing as a leading partner in specialty and community care.
